Illuminare Biotechnologies

Illuminare Biotechnologies operates at the intersection of biotechnology and medical devices, targeting intraoperative nerve visualization rather than broad diagnostic imaging. Its product, Illuminare-1, is described as a small-molecule agent that binds to myelin so nerves can be seen during surgery. The company says visualization begins five minutes after injection and persists for the duration of the procedure, an approach intended to fit within surgical workflows and help reduce nerve damage risk. The company is listed in biotechnology, health care, and medical-device categories, but the available profile does not identify verifiable peer companies or provide evidence for a direct competitor comparison. Accordingly, its differentiation can be described at the product-mechanism level—myelin binding and intraoperative nerve highlighting—rather than as a demonstrated market advantage.

The company’s recorded timeline spans an early Venture Round on August 18, 2017, followed by a long gap in funding milestones before a Series B entry dated July 14, 2026. The earlier round accounts for the full $2,373,677 reported as total funding; no amount is specified for the Series B, so the available total may not capture all capital raised. A November 6, 2025 Phase 1 announcement for Rizedisben provides a clinical-development milestone, while the June 1, 2026 leadership transition brought Brian Longstreet into the CEO role and moved Walter Greenblatt to chairman and CFO. The company’s profile lists six current executive positions and an employee range of one to ten, suggesting a small organization, but it does not provide a time series for headcount or evidence of workforce growth. Overall, the visible inflection points are clinical disclosure, executive succession, and a Series B listing, while the financing amount and next development steps remain unclear.